Icon (NASDAQ:ICLR) Stock Sold Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold $15,001–$50,000 of Icon stock on August 14 from the Hern Family Foundation account. He also reported sales of several other holdings, including Home Depot, Procter & Gamble, Microsoft and Medtronic.
• Icon reported quarterly earnings of $2.56 per share, narrowly beating estimates, while revenue reached $2.06 billion and rose 2.3% year over year.
• Analyst sentiment remains mixed: Icon has a consensus “Hold” rating and a $170.40 target price, while institutional investors own 95.61% of the company’s stock.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Icon Plc NASDAQ: ICLR. In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Icon stock on August 14th. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Medtronic NYSE: MDT on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Home Depot NYSE: HD on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Procter & Gamble NYSE: PG on 8/24/2026.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Veralto NYSE: VLTO on 8/21/2026.
• Sold $15,001 - $50,000 in shares of Honeywell Aerospace NASDAQ: HONA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Colgate-Palmolive NYSE: CL on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Biogen NASDAQ: BIIB on 8/18/2026.

Icon Price Performance

Shares of Icon stock opened at $159.84 on Thursday. Icon Plc has a one year low of $66.57 and a one year high of $203.91. The stock's fifty day moving average is $168.10 and its 200 day moving average is $134.82. The stock has a market cap of $12.24 billion, a P/E ratio of 37.52, a P/E/G ratio of 6.68 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95.

Icon (NASDAQ:ICLR - Get Free Report) last released its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.26 earnings per share. Sell-side analysts anticipate that Icon Plc will post 9.58 earnings per share for the current year.

Hedge Funds Weigh In On Icon

Large investors have recently modified their holdings of the stock. WINTON GROUP Ltd bought a new position in shares of Icon during the second quarter valued at approximately $254,000. Daiwa Securities Group Inc. increased its holdings in Icon by 19.3% during the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after buying an additional 4,546 shares during the period. Frontier Capital Management Co. LLC raised its position in shares of Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock worth $10,379,000 after acquiring an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp bought a new position in Icon in the second quarter worth about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after acquiring an additional 289 shares in the last quarter. Institutional investors own 95.61% of the company's stock.

Insider Buying and Selling

In other news, Director Ronan Martin Murphy sold 841 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the sale, the director directly owned 3,847 shares of the company's stock, valued at $632,023.63. The trade was a 17.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $439,804.33. Following the completion of the transaction, the director directly owned 20,452 shares in the company, valued at $3,360,059.08. This represents a 11.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,531 shares of company stock valued at $1,565,764 in the last 90 days. 44.00% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on ICLR shares. Bank of America upped their target price on shares of Icon from $125.00 to $150.00 and gave the stock an "underperform" rating in a report on Thursday, June 25th. Truist Financial reaffirmed a "buy" rating and set a $209.00 price objective (up from $207.00) on shares of Icon in a report on Friday, July 31st. Citigroup lifted their price objective on shares of Icon from $165.00 to $180.00 and gave the company a "neutral" rating in a research report on Friday, July 31st. DA Davidson set a $164.00 price objective on Icon in a research report on Monday, June 1st. Finally, William Blair raised Icon to a "strong-buy" rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $170.40.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Icon

Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source